Anaptysbio (ANAB) Consolidated Net Income (2016 - 2026)

Anaptysbio has reported Consolidated Net Income for 11 years, with the latest figure at -$52.9 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 34.47% year-over-year to -$52.9 million; the trailing twelve-month figure through Mar 2026 stood at -$13.7 million (up 90.25% YoY), and the FY2025 full-year result was -$164000.0, up 99.89% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$52.9 million, down from $62.7 million in the prior quarter.
• The five-year high for Consolidated Net Income was $121.4 million in Q4 2023, with the low at -$52.9 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$17.7 million across 5 years, with a median of -$32.9 million in 2024.
• Annual changes were most pronounced in 2022 — Consolidated Net Income sank 6121.91% — and 2023, when it soared 648.34%.
• Anaptysbio's Consolidated Net Income stood at -$22.1 million in 2022, then soared by 648.34% to $121.4 million in 2023, then tumbled by 118.06% to -$21.9 million in 2024, then surged by 385.92% to $62.7 million in 2025, then plunged by 184.37% to -$52.9 million in 2026.
• The last three Consolidated Net Income figures came in at -$52.9 million (Q1 2026), $62.7 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.